Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
iTeos Therapeutics (ITOS)
NASDAQ:ITOS
Holding ITOS?
Track your performance easily
ITOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.66 - $18.75
Previous Close$7.85
Volume825.65K
Average Volume (3M)688.10K
Market Cap
$288.62M
Enterprise Value-$194.56M
Total Cash (Recent Filing)$488.71M
Total Debt (Recent Filing)$5.53M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 19, 2025EPS Estimate
-$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding36,533,918
10 Day Avg. Volume492,647
30 Day Avg. Volume688,096
Standard Deviation0.20
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)8.25
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-5.56
Enterprise Value/Gross Profit-15.45
Enterprise Value/Ebitda1.60
Forecast
1Y Price Target
$37.67Price Target Upside363.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
iTeos Therapeutics News
PremiumCompany Announcements
iTeos Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Officina Stellare Secures €1.4 Million Satellite Contract
PremiumCompany Announcements
iTeos Therapeutics Reports Positive Phase 2 Cancer Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsThe positive interim data from the Phase 2 GALAXIES Lung-201 study showed a competitive drug profile of belrestotug plus dostarlimab for the treatment of PD-L1-high NSCLC.
Drug EfficacyAt a relatively immature 7.3 months median follow-up, and over the three dose arms, the combination demonstrated a confirmed 61% overall response rate (ORR), which is 33 percentage points higher than the dostar arm at 28%.
Financial OutlookThe company ended 3Q24 with $649MM in cash, providing runway through 2027, enough to address multiple catalysts.
Bears Say
Competitive LandscapeEven though belrestotug and tiragolumab, if approved, could have first-to-market advantage in the anti-TIGIT space, they could eventually face strong competition from Fc-reduced/silenced anti-TIGIT therapies.
Safety ConcernsThe safety data of the GALAXIES Lung-201 study confirms belief that Fc-competent anti-TIGIT antibodies are associated with increased risk of immune-related adverse events.
Stock PerformanceThe stock is down -16% YTD, likely due to low confidence in the company's lead program belrestotug.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ITOS FAQ
What was iTeos Therapeutics’s price range in the past 12 months?
iTeos Therapeutics lowest stock price was $7.66 and its highest was $18.75 in the past 12 months.
What is iTeos Therapeutics’s market cap?
Currently, no data Available
When is iTeos Therapeutics’s upcoming earnings report date?
iTeos Therapeutics’s upcoming earnings report date is Mar 19, 2025 which is in 117 days.
How were iTeos Therapeutics’s earnings last quarter?
iTeos Therapeutics released its earnings results on Nov 12, 2024. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.171 by $0.121.
Is iTeos Therapeutics overvalued?
According to Wall Street analysts iTeos Therapeutics’s price is currently Undervalued.
Does iTeos Therapeutics pay dividends?
iTeos Therapeutics does not currently pay dividends.
What is iTeos Therapeutics’s EPS estimate?
iTeos Therapeutics’s EPS estimate is -$1.05.
How many shares outstanding does iTeos Therapeutics have?
iTeos Therapeutics has 36,533,916 shares outstanding.
What happened to iTeos Therapeutics’s price movement after its last earnings report?
iTeos Therapeutics reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.171. Following the earnings report the stock price went down -2.026%.
Which hedge fund is a major shareholder of iTeos Therapeutics?
Among the largest hedge funds holding iTeos Therapeutics’s share is RA Capital Management. It holds iTeos Therapeutics’s shares valued at 33M.
---
iTeos Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (363.35% Upside)
$37.67 (363.35% Upside)
Blogger Sentiment
Bullish
ITOS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $38.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.96%
12-Months-Change
Fundamentals
Return on Equity
-19.72%
Trailing 12-Months
Asset Growth
6.70%
Trailing 12-Months
Company Description
iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
---
ITOS Stock 12 Month Forecast
Average Price Target
$37.67
▲(363.35% Upside)
Technical Analysis
Best Analysts Covering ITOS
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-17.13%
assigned a buy rating 2 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -17.13% per trade.
---